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Abstract
 Background—Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a relatively 
newly identified autoimmune neuropsychiatric disorder that predominantly affects children and 
young adults. Although psychiatric symptoms are highly prevalent and frequently severe, it has 
mainly been reported in neurological, but not psychiatric, literature. Understanding this form of 
encephalitis, its quick diagnosis and which treatment to provide are of utmost importance for 
consultation-liaison (C-L) psychiatrists. The aim of this paper was to describe a case of anti-
NMDAR encephalitis with severe psychiatric manifestations, who showed impressive recovery but 
required intensive involvement of the C-L psychiatry team. We emphasise the behavioural aspects, 
psychiatric symptoms and challenges faced by the CL consultant across the different phases of the 
treatment.
 Methods—We report the different treatment phases for a young woman with anti-NMDAR 
encephalitis who developed severe neuropsychiatric symptoms, with a focus on the role and 
challenges faced by the C-L psychiatrist. The literature is reviewed for each of these challenges.
 Results—This case illustrated that even extremely severely affected patients may show 
impressive recovery, but require long lasting psychiatric care. C-L psychiatrists are faced with 
numerous challenges where only little literature is available.
 Conclusion—C-L psychiatrists play a pivotal role throughout the multidisciplinary care of 
patients with anti-NMDAR encephalitis and should be informed about this entity.
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Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a subtype of a recently 
described autoimmune disorder of the brain. It was first described in 2005 and subsequently 
has been characterized mainly in the neurological literature [1,2]. There are surprisingly few 
reports in psychiatric journals, given that patients with anti-NMDAR encephalitis often 
present with psychiatric symptoms including psychomotor agitation, impulsivity and 
disinhibition, mood swings, delusional thoughts, paranoia, and hallucinations [3]. Up to 25% 
of patients may have a poor outcome, with persistent, severe neuropsychiatric deficits or 
even die [2,4]. Understanding this entity, performing a quick diagnosis and deciding 
treatment are important for consultation-liaison (C-L) psychiatrists.
In this paper we illustrate the challenges faced by the C-L consultant across different phases 
of the treatment of a young woman with severe encephalitis, who displayed cognitive 




A 22-year-old female university student with no medical and psychiatric history 
spontaneously presented to the emergency unit of our university hospital, complaining of 
speech disorders, physical and mental fatigue. Four days earlier she had developed a 
stuttering episode with concentration difficulties. A side effect of a recently prescribed 
antihistaminic drug (cetirizine) was suspected, and the medication was stopped. She was 
discharged home. Two days later, she was readmitted to the hospital because of an increase 
in subtle chorei form movements (perioral, hands), as well as memory impairment. She also 
presented with decreased mobility, lack of right hand grip, paraesthesia of the left hemibody, 
dysarthria, and tinnitus. Figure 1 illustrates the intensity of neurological and psychiatric 
symptoms throughout the different phases of the disease.
 First intensive care unit (ICU) phase: Coma
In the following days, her orofacial dyskinesia worsened and she developed a swallowing 
disorder, speech deterioration, vomiting, wide pupils and facial flush, right upper limb 
weakness associated with paranoid delusions, as well as auditory and olfactory 
hallucinations. Over the following 2 weeks she developed delirium and increased 
impairment of consciousness, requiring endotracheal intubation and ventilation in the ICU. 
A large differential diagnosis was considered, including most common causes of 
encephalitis: viral, autoimmune, paraneoplastic and toxic-metabolic. Electroencephalogram 
(EEG) performed shortly after inpatient admission (2 weeks after the initial symptoms) was 
suggestive of anti-NMDAR encephalitis, showing poorly reactive rhythmic delta activity 
over the frontal regions [5]. This was confirmed by a positive anti-NMDAR antibody test in 
cerebrospinal fluid and serum (Serum: 1/100, Cerebrospinal fluid: 1/2). A nodule in the right 
ovary observed by ultrasound and removed by laparoscopy did not show a tumoural lesion 
by histology (no teratoma).
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During the following months, the patient, while unconscious and mechanically ventilated, 
received specific immunological treatments (high-dose steroids, 15 cycles of plasma 
exchange, 8 cycles of cyclophosphamide, 4 cycles of rituximab, and 4 cycles of intravenous 
immunoglobulin), with high-dose midazolam (and at times propofol) sedation. Although we 
did not formally identify a clinical or electrographic seizure, she received non-sedating 
intravenous antiepileptic treatment (valproic acid and lacosamide), because the rhythmic 
delta activity by EEG represented an ictal correlate [6]. Her clinical course was 
characterized by hemodynamic, breathing, cardiac arrhythmias, infectious, metabolic, and 
nutritional dysfunctions. Throughout this long “unresponsive phase” there was no contact 
with the patient. Sometimes she opened her eyes but remained mute and unresponsive to 
visual stimuli. Orofacial and arm dyskinesia were regularly present upon weaning of the 
sedation, and her EEG showed a rhythm delta over the frontal regions alternating with a 
disorganized, relatively fast activity.
 Second ICU phase: Awake
After several months of being in an unresponsive state in the ICU under continuous 
immunotherapy, the patient started to improve. Limited contact became possible: she opened 
her eyes and responded to simple orders. She was finally extubated eight months after her 
admission. After awakening, the patient presented with an acute confusional state but her 
neurological status improved slowly. Over the following weeks, she was slow and 
hypomimic with ataxic movements. However, delirium persisted with episodes where she 
was mute, a kinetic, and unresponsive to verbal commands. For four months the patient 
presented with severe psychopathological manifestations.
1. Episodes of psychomotor agitation with overt aggressive behaviour were 
very challenging, including throwing objects around the room, slapping 
her hands on the bed, trying to pull out the feeding tube, sometimes 
requiring sedation (intravenous midazolam and propofol) and even 
physical restraint for short periods.
2. Psychotic features were clearly recognizable upon speaking indicating 
paranoid delusions as well as auditory and olfactory hallucinations. She 
was also tremendously anxious or perplexed, and refused contact (e.g. 
actively kept her eyes closed) with the ICU staff or even with her family.
3. Affective elements were also present, including depressive withdrawal, 
suicidal ideation culminating in attempted self-harm by knife or 
strangulation with a cable. She also presented with severe insomnia and 
nightmares.
4. Interactions with her caregivers were marked by irritability and 
emotional manifestations, recurrent refusal of care and feeding, and even 
requests to be killed or that we let her die. This highly challenging 
situation for the ICU team required that an additional nurse be hired 
allowing “one to one” continuous supervision of the patient to prevent 
accidents.
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Besides midazolam and propofol she received quetiapine XR (orally through a nasogastric 
tube). Despite benzodiazepine and antipsychotic treatments, the patient remained impulsive 
and aggressive with psychotic symptoms for several weeks. An improvement occurred after 
1 month when quetiapine XR was increased to 600 mg/day. In parallel, physiotherapy was 
started in the ICU to improve swallowing and reduce feeding difficulties. A specific team 
(not the C-L team) delivered these therapies. The neuropsychological rehabilitation therapies 
were used to target attention disorders, immediate and episodic anterograde memory, and 
language disorders such as dysarthria, lack of words and ideomotor apraxia.
Four months after coma resolution (12 months after admission), we observed a significant 
improvement that was chronologically linked to a decrease in plasma anti-NMDAR 
antibodies. A further increase of quetiapine allowed a low tapering of benzodiazepines, at 
which time, there was a complete disappearance of psychomotor agitation. However, 
hallucinations as well as feelings of sadness, anger, and fluctuating suicidal ideation were 
still present.
 Rehabilitation phase
 Residual psychotic and affective symptoms—Five months after coma resolution, 
the patient was transferred to a psychiatric unit for management and treatment of the 
residual psychotic symptoms. Her autonomy increased and she better engaged in social 
interactions with therapists and other patients. She was collaborative in psychiatric 
consultations, physiotherapy and occupational therapy activities. She began to take better 
care of her body, applying make-up or asking for an appointment with the hairdresser. 
Contacts with family and friends were more frequent and a source of pleasure. She started to 
make plans for her future (wish to be discharged home and return to her university studies). 
After 2 months at the psychiatric unit, the psychotic and affective symptoms gradually 
resolved.
 Reversible cognitive impairment—At that point, cognitive deficits were still present, 
with attention disorders, deficits in immediate and episodic anterograde memory, language 
disorders (dysarthria, lack of words, paraphasia and agrammatism), and ideomotor apraxia. 
The patient was transferred to a neurorehabilitation unit (NRU) for about 6 weeks. She was 
trained by neuropsychological tasks and showed improved interference management, 
information retention in episodic and verbal memory, and mental calculations. Furthermore, 
she benefited from intensive ergotherapeutic and physiotherapeutic approaches. In particular, 
ergotherapy by NRU staff focused on cognitive, speech-language deficits, communication 
skills and social-motivational occupations. The clinical evolution was remarkably good, with 
an improvement in cognitive and executive functions and social organizational activities.
 Gradual recovery—Sixteen months after her first contact with our hospital, the patient 
was discharged home. She was followed up by liaison psychiatry consultation once a week. 
She took quetiapine (300 mg/day) treatment for 6 more months, which was then successfully 
discontinued. Nine months after discharge, the patient and her parents reported social, 
personal and family stability. The patient resumed university attendance and successfully 
passed her exams. She has little recollection of the 16 months of admission and treatment, 
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particularly the ICU phase. At the last follow-up, 2 years after the event, she only 
complained about the tracheostomy scar.
 Discussion
This study reports the case of a young woman presenting with anti-NMDAR encephalitis, an 
autoimmune and paraneoplastic disorder that affects young adults and may be associated 
with tumours (ovarian teratoma) in up to 50% of cases [2]. Anti-NMDAR encephalitis has 
been recently described following the ability to measure this antibody. Most patients develop 
a complex syndrome, initially presenting with psychosis and behavioural disturbances and 
rapidly progressing to develop speech problems, memory deficits, consciousness 
impairment, movement disorders, seizures, dysautonomia, and respiratory deregulation. 
Although some authors describe very distinct clinical phases [7], an exact sequential 
development of stages is not always observed. For example, the presenting symptoms (e.g. 
more frequent psychiatric episodes in younger adults and teenagers, more frequent seizures 
or dyskinesias in young children), development of a full blown syndrome, or clinical course 
and relapses can vary among patients [8–11]. Furthermore, a recent study highlighted the 
possibility of isolated psychiatric presentation (without neurological symptoms) [12], and 
Soe et al. recently described the first case of β-Thalassemia trait association with anti-
NMDAR encephalitis in a 10-year-old girl [13]. Our case illustrates that even extremely 
severely affected patients may show impressive recovery but require long-term psychiatric 
care. C-L psychiatrists are faced with numerous challenges (Figure 1) because of a lack of 
available literature.
The care of our patient required the involvement of numerous disciplines as well as several 
medical structures (ICU, acute neurology, NRU, psychiatric facilities). The special position 
of the C-L consultant not only required collaboration with all these disciplines but also 
provided continuity throughout the entire period of care. This aspect appeared to be of 
utmost importance to the patient at several time points. Our role with ICU or NRU staff 
included education, support, managing counter transference to the patient and C-L team, 
advice on pharmacotherapy and behavioural approaches.
Here we focus on the main challenges and strategies employed by the C-L psychiatrist 
(Figure 1).
 Diagnostic Challenges
In many cases of anti-NMDAR encephalitis, especially early in the course of the disease, 
symptoms and behaviours mimicking psychotic or mood/anxiety disorders, such as 
hallucinations, delusions, anxiety, depressive symptoms and fatigue are observed. In our 
patient, the rapid progression of mental fatigue and concentration difficulties to psychotic 
symptoms and auditory and olfactory hallucinations together with neurological impairment 
(delirium, abnormal movements, speech deterioration) were highly suggestive of an organic 
cause, rather than a primary psychiatric disorder. Important differential diagnoses apart from 
encephalitis, included serotonin and neuroleptic malignant syndromes given that 
neurological symptoms (hyperreflexia, myoclonus, restless syndrome, rigidity, behavioural 
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disorders) and delirium can be present in both [4,14]. Tricyclics, selective serotonin reuptake 
inhibitors, antidepressants, and neuroleptics may induce autonomic dysregulation as well as 
hyperreflexia, myoclonus, restless leg syndrome, rigidity, behavioural disorders and 
delirium. Without treatment, the clinical picture can evolve into malignant hyperthermia, 
muscular rigidity, dyskinesia progressing to unstable blood pressure and autonomic 
dysregulation [4,14]. In our case, a detailed history provided by her family and treating 
physician allowed the exclusion of antipsychotic and/or antidepressant use before symptom 
onset. Based on this clinical presentation and the EEG, a suspicion of anti-NMDAR 
encephalitis was finally confirmed by blood test.
 Behavioural Challenges
Our C-L psychiatric team had to face a patient with severe psychomotor agitation, 
aggressive behaviour, psychotic manifestations, suicidal ideation and irritability towards 
caregivers and her family for many months. Pharmacological and non-pharmacological 
strategies were applied.
 Pharmacological Strategies
In our case, suppression of the immune response improved neurological signs slowly but 
initially had no impact on psychiatric symptoms. The patient was easier to manage when 
sedated in the ICU, compared with the second period in the ICU when she awoke and had 
marked psychiatric symptoms (Figure 1). Literature for the pharmacological management of 
psychiatric and behaviour symptoms in the context of anti-NMDAR encephalitis is sparse 
but suggests the use of atypical (olanzapine, quetiapine, risperidone, ziprasidone) 
antipsychotics and in extreme conditions, phenobarbital, benzodiazepines, or fentanyl, to 
induce a medical coma [12,15]. All antipsychotics must be employed with caution because 
they can exacerbate motor symptoms, worsen a malignant catatonia (a possible later 
complication induced by encephalitis progression), or trigger neuroleptic malignant 
syndrome [4,16]. Benzodiazepines (lorazepam) can be effective in cases of catatonia, but 
few published reports describe the use of electroconvulsive therapy if catatonia is 
benzodiazepines-resistant [15,17,18]. Anecdotal case reports show that lithium and valproic 
acid use can treat mood dysregulation symptoms in anti-NMDAR encephalitis [19,20]. In 
our case, the use of quetiapine up to 600 mg/day after 3–4 weeks coupled with high doses of 
benzodiazepines (midazolam 4 mg i.v. per hour) and Propofol to treat agitation was an 
efficacious strategy. We faced a risk/benefit dilemma between the need for sedation and the 
risk of triggering or perpetuating delirium. Midazolam and propofol are potent sedative 
agents but are delirium risk factors. These treatments were initiated by ICU physicians. The 
role of the C-L psychiatrist was to frequently remind the ICU of this risk and try to optimize 
the risk/benefit for the patient. Each drug administration and increase in benzodiazepine or 
neuroleptic dosage was carefully monitored. We prescribed the lowest possible dose with 
optimal distribution over the day, and avoided polypharmacy interactions. We measured 
cardiac QT interval to evaluate and limit the risk of arrhythmia, “torsade de pointes” and the 
risk of sudden death [21,22]. Furthermore, to optimize the treatment, we conducted frequent 
therapeutic drug monitoring (TDM) of psychotropic drugs based on the Arbeitsgemeinschaft 
für Neuropsychopharmakologie und Pharmakopsychiatrie (Association for 
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Neuropsychopharmacology and Pharmacopsychiatry) guidelines for TDM in psychiatry 
[23,24]. We followed the recommendations for drug concentrations and laboratory alert 
levels. We also obtained advice from the Psychopharmacology Unit of our University 
Hospital.
 Non-pharmacological strategies
We found no studies examining the role of non-pharmacological interventions to treat 
behavioural disorders in the context of anti-NMDAR encephalitis. In our case, the main 
objective of the medical team was to ensure the safety of the patient and reduce psychomotor 
agitation. We faced some extreme violent behaviour as well as treatment-resistant visual, 
auditory and olfactory hallucinations during several weeks.
General hospitals in Switzerland use written protocols for authorizing and providing 
physical or chemical restraint. These protocols are prescribed by the physician in charge 
with the advice and supervision of the C-L psychiatric team. The duration must be strictly 
limited. In our case, restraint was applied for the shortest time possible and only at times 
when the patient had low discernment capacity. When restraint was applied, it was discussed 
at least twice a day with the team and monitored according to a formal written protocol 
regulating physical restraint. Throughout the difficult phases we took great care to try to 
reorient the patient, to explain the context of care, and answer her questions. During the 
prolonged stay in the ICU, our role with medical staff included support and managing 
countertransference. In particular, the negative attitudes of the team expressed through 
aggressive comments and disinvestment in the care of the patient were discussed in 
multidisciplinary team meetings.
 Rehabilitation Challenges
Five months after coma resolution, the patient was admitted to the psychiatric unit for 2 
months, as psychiatric symptoms were still too severe to follow up directly with a 
rehabilitation program. Transfer to psychiatric hospital was also discussed at several 
multidisciplinary meetings. Moreover, the psychiatric hospital team representative discussed 
the transfer to ensure a smooth transition between the somatic and psychiatric ward.
Throughout the psychiatric unit period, residual psychotic symptoms (affective flattening, 
apathy and social withdrawal) were the new focus of treatment. Frequent psychiatric 
consultations, occupational therapy activities, and contact with her family provided a good 
psychiatric outcome.
Our patient was then transferred to the NRU for about 6 weeks. There is limited literature for 
the long-term rehabilitation of patients with anti-NMDAR encephalitis. A recent clinical 
case conference demonstrated the necessity of individualizes treatments and targeting 
different strategies depending on the type of clinical presentation [20]. The authors 
suggested combining physical and occupational therapies to target different deficits after a 
long hospital stay. According to the type of deficit, different clinical techniques are 
employed including speech-language work, re-feeding strategies after prolonged ventilation, 
physiotherapy for the recovery of coordination and simple walking. For memory 
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impairment, a recent report reported long-term cognitive outcomes in nine patients with anti-
NMDAR encephalitis [25]. The authors observed that cognitive deficits (mainly impairments 
in executive functions and memory) may be present for a long period after resolution of the 
acute stage of anti-NMDAR encephalitis. Furthermore, the severity of cognitive impairment 
showed inter-individual variation and depended on disease course and treatment onset. This 
suggests the importance of early and aggressive treatment by immunotherapy to limit or 
prevent a later cognitive impairment. In our patient, treatment targeted attention disorders, 
immediate and episodic anterograde memory, language disorders as dysarthria, lack of 
words and ideomotor apraxia. Ergotherapy focused on cognitive, speech-language deficits, 
communication skills and social-motivational occupations. Physiotherapy was useful to 
provide better coordination. After discharge from the NRU, the patient was followed up for a 
couple of months by our C-L psychiatric outpatient unit. The main goal was to allow 
verbalization of emotional experiences such as the fear of death and of a relapse. Given the 
limited recollection of the 16-month hospital admission, the patient was in need of retracing 
the story of the different phases of the disease: this step allowed a reappropriation of this 
dramatic episode of her life. Moreover, the patient was in need of support to regain her 
desire for emancipation as a young adult woman who is responsible for her future.
 Conclusion
Anti-NMDAR encephalitis is a newly described pathology at the interface between 
neurology and psychiatry. It is important to improve the knowledge of C-L psychiatrists with 
regard to this organic condition that frequently presents with severe psychiatric symptoms. 
Multidisciplinary collaboration is important throughout the different phases of this disease.
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Intensity and duration of neurological and psychiatric symptoms through the different 
phases of the anti-NMDAR encephalitis.
Note: ICU, intensive care unit; NRU, neuro rehabilitation unit; Anti-NMDAR, anti-N-
methyl-D-aspartate receptor
Course of neurological symptoms: abnormal movements, paraesthesia, swallowing 
disorders, speech deterioration, delirium, autonomic dysregulation, coma, and gradual 
recovery.
Course of psychiatric symptoms: mental fatigue, concentration difficulties, psychotic 
symptoms, delirium, coma, acute confusional state, severe behavioural disorders 
(psychomotor agitation, psychotic symptoms, suicidal ideation, irritability and emotional 
manifestations towards caregivers), residual psychotic symptoms (affective flattening, 
apathy and social withdrawal sadness, anger, fluctuating suicidal ideation), and gradual 
recovery.
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